R&D-based big pharma groups in China with sufficient cash flow are increasing their strategic investments in overseas companies and products with an eye on entry to the global market, while start-ups continue to actively raise new funds from venture capitalists.

Nestle Health and Hutchison China MediTech’s JV has an ongoing phase III trial hoping to validate traditional Chinese medicine for Western health care systems. Reports of TCM contamination at China-based firms represent a market-incursion opportunity for Western firms with established supply chains.

Nestle Health and Hutchison China MediTech’s JV has an ongoing phase III trial hoping to validate traditional Chinese medicine for Western health care systems. Reports of TCM contamination at China-based firms represent a market-incursion opportunity for Western firms with established supply chains.

A joint venture between Nestle Health and Hutchison China MediTech is amid an ongoing Phase III trial hoping to validate traditional Chinese medicine for Western health care systems. New reports of TCM contamination in China offer a glimpse of opportunity for Western entries.